Global Preeclampsia Diagnostics Market Size study & Forecast, by Test Type (Blood Tests, Urine Analysis), by Product (Instruments, Consumables), by End-User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) and Regional Analysis, 2022-2029

Global Preeclampsia Diagnostics Market Size study & Forecast, by Test Type (Blood Tests, Urine Analysis), by Product (Instruments, Consumables), by End-User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) and Regional Analysis, 2022-2029

Global Preeclampsia Diagnostics Market is valued at approximately USD 1.03 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 2.2% over the forecast period 2022-2029. Preeclampsia, commonly referred to as toxaemia, is a progressively growing condition marked by raised blood pressure and high protein in pregnant women's urine. One of the hypertensive disorders of pregnancy that accelerates maternal and perinatal morbidity and mortality rates among women in industrialized and developing countries is this one. The Preeclampsia Diagnostics market is expanding because of factors such as increasing incidence of Preeclampsia among female population, and growing focus on the development of innovative preeclampsia diagnostic products.

Pregnant women globally are likely to have a rising demand for early preeclampsia diagnosis, which is anticipated to fuel the expansion of the global preeclampsia diagnostics market over the forecast period. For instance, the Preeclampsia Foundation predicts that over 10 million women worldwide suffer from preeclampsia each year and that preeclampsia contributes to over 2.5 million preterm births. Furthermore, Preeclampsia affected at least 1 in 7 deliveries during this time, according to the Centers for Disease Control and Prevention, and its prevalence among hospitalisations for childbirth increased from around 13% in 2017 to 16% in 2019. Another important component driving space increase is increase in funding for diagnosis and treatment of Preeclampsia. For instance, on February 2, 2022, the Preeclampsia Foundation and Preeclampsia Foundation Canada, its Canadian affiliate, would each award one medical research Vision Grant, up to US$ 20,000, for the study of preeclampsia and related hypertensive diseases of pregnancy. However, less awareness about preeclampsia may halt market growth.

The key regions considered for the Global Preeclampsia Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue. The market expansion in this region is attributed to the increasing adoption of technologically improved goods, rising patient and healthcare provider awareness of the seriousness of the disease, and considerable healthcare spending. Additionally, the industry is projected to rise as more cutting-edge preeclampsia diagnostics products are introduced. Whereas Europe is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising target populations. Further, a sizable patient base with hypertensive problems during pregnancy is expected to fuel market growth. Additionally, a rise in government healthcare organizations’ approvals of the diagnosis of hypertensive problems in pregnancy may promote market expansion in Europe.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd
PerkinElmer Inc.
DRG instruments GMBH
Thermo Fisher Scientific Inc.
Diabetomics, Inc.
Metabolomic Diagnostics Ltd.
Sera Prognostics
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter, Inc.)
Bio-Rad Laboratories, Inc.

Recent Developments in the Market:
In June 2021, In India, LifeCell Diagnostics introduced a thorough preeclampsia screening programme. The sophisticated screening finds sFLT-1 (soluble FMS-like tyrosine kinase-1), a biomarker that allows for reliable diagnosis even in the third trimester and allows for illness prediction.
In July 2019, The Preeclampsia Foundation and Predictive Laboratories, Inc. formed a research partnership. The objective of this collaboration is to create a tailored test for the early identification of risk in disease-affected women.




Global Preeclampsia Diagnostics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Test Type, Product, End-User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World





The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Test Typeofferings of key players.

The detailed segments and sub-segment of the market are explained below:

By Test Type:
Blood Tests
Urine Analysis

By Product:
Instruments
Consumables

By End-User:
Hospitals
Specialty Clinics
Diagnostic Centers
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

F. Hoffmann-La Roche Ltd
PerkinElmer Inc.
DRG instruments GMBH
Thermo Fisher Scientific Inc.
Diabetomics, Inc.
Metabolomic Diagnostics Ltd.
Sera Prognostics
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter, Inc.)
Bio-Rad Laboratories, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.